チロシンプロテインキナーゼFyn治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0493
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:103
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD10,500 ⇒換算¥1,102,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Tyrosine Protein Kinase Fyn – Pipeline Review, H2 2019
Summary

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Tyrosine Protein Kinase Fyn – Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 3, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Respiratory, Women’s Health, Cardiovascular, Hematological Disorders, Male Health, Metabolic Disorders and Musculoskeletal Disorders which include indications Parkinson’s Disease, Alzheimer’s Disease, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometriosis, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Asthma, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cancer Pain, Chronic Obstructive Pulmonary Disease (COPD), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Follicular Lymphoma, Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Idiopathic Pulmonary Fibrosis, Lymphangioleiomyomatosis, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Oligodendroglioma, Ovarian Cancer, Peritoneal Cancer, Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Psychosis, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Secondary Progressive Multiple Sclerosis (SPMS), Transformed Mycosis Fungoides and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Overview
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Companies Involved in Therapeutics Development
AB Science SA
AstraZeneca Plc
Bristol-Myers Squibb Co
MAA Laboratories Inc
PK Biosciences Corp
ValiRx Plc
Zen-Bio Inc
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Drug Profiles
CP-14028 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CP-15078 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit BLK, FYN and LYN Kinase for Blood Cancer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAL-301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Dormant Products
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Discontinued Products
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) – Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: VALIRX : VAL201 update
Dec 02, 2019: AB Science provides the summary of webcast with Key Opinion Leaders on masitinib Phase 3 results in severe asthma uncontrolled by oral corticosteroids
Nov 28, 2019: VALIRX: US patent grant for the use of VAL201 in the prevention and treatment of metastatic cancer
Nov 26, 2019: AB Science will host a live webcast on masitinib in severe asthma on December 2, 2019
Nov 25, 2019: AB Science provides the summary of webcast with Key opinion leaders on Indolent Systemic Mastocytosis
Nov 07, 2019: AB Science announces positive top-line Phase 3 results for oral masitinib in severe asthma
Nov 04, 2019: AB Science will host a live webcast on indolent systemic mastocytosis on November 20, 2019
Oct 24, 2019: AB Science granted authorization to initiate phase 3 confirmatory study of Masitinib in indolent systemic mastocytosis
Oct 10, 2019: AB Science provides update on masitinib programs timelines
Sep 10, 2019: VALIRX provides update on its prostate cancer drug candidate VAL201
Aug 12, 2019: AB Science to present at two upcoming conferences in September 2019
Aug 05, 2019: AB Science provides an update on its masitinib clinical program
Aug 02, 2019: AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
Jul 08, 2019: AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Jul 04, 2019: ValiRx progresses VAL301 clinical development plan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AB Science SA, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by MAA Laboratories Inc, H2 2019
Pipeline by PK Biosciences Corp, H2 2019
Pipeline by ValiRx Plc, H2 2019
Pipeline by Zen-Bio Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

【掲載企業】

AB Science SA
AstraZeneca Plc
Bristol-Myers Squibb Co
MAA Laboratories Inc
PK Biosciences Corp
ValiRx Plc
Zen-Bio Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[チロシンプロテインキナーゼFyn治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆